C4 Therapeutics (CCCC) Assets (2019 - 2026)

C4 Therapeutics' Assets history runs 8 years deep, the most recent figure standing at $328.9 million for Q1 2026.

• In Q1 2026, Assets rose 2.92% year-over-year to $328.9 million; the TTM figure through Mar 2026 stood at $328.9 million (up 2.92% YoY), while the FY2025 annual figure was $359.1 million, up 2.71% from the prior year.
• Assets was $328.9 million for Q1 2026 at C4 Therapeutics, down from $359.1 million in the prior quarter.
• In the past five years, Assets ranged from a high of $515.5 million in Q1 2022 to a low of $265.5 million in Q3 2025.
• Historically, Assets has averaged $379.7 million across 5 years, with a median of $376.1 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Assets soared 37.83% in 2022, then dropped 29.4% in 2025.
• A 5-year view of Assets shows it stood at $430.8 million in 2022, then retreated by 12.62% to $376.5 million in 2023, then dropped by 7.13% to $349.6 million in 2024, then increased by 2.71% to $359.1 million in 2025, then slipped by 8.41% to $328.9 million in 2026.
• The last three Assets figures came in at $328.9 million (Q1 2026), $359.1 million (Q4 2025), and $265.5 million (Q3 2025), per Business Quant data.